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published in the Journal of Microbiology, Immunology, and Infection, who reported a patient with fulminate Aeromonas hydrophila soft tissue infection and septicemia during acute lymphoblastic leukemia treatment. After combination therapy with antibiotics and surgical management, the patient recovered well. The case reminds us of the possibility of Aeromonas infection in cancer patients; however, knowledge about this clinical entity is limited. This study was intended to investigate retrospectively the clinical manifestation of Aeromonas-related skin and soft tissue infections (SSTIs) in cancer patients to understand this issue better.
This study was conducted at the Chi Mei Medical Center, a 900-bed hospital. This hospital is located in southern Taiwan, 2 where the Aeromonas infection is endemic, and most of the patients treated at the hospital are cancer patients. This retrospective study enrolled patients with culture-confirmed Aeromonas infection during the period January 2009eDecember 2011. SSTIs were diagnosed in patients who presented with pain, swelling of the involved site, and patchy, edematous, erythematous, or bullous skin lesions. Necrotizing fasciitis was defined as necrosis of the subcutaneous tissue and adjacent fascia due to severe infection. All isolates were identified by conventional methods and verified further following the procedure described in our previous study. 3 Polymicrobial infections were diagnosed in patients from whom Aeromonas species, in addition to other pathogens, were isolated from cutaneous specimens. In-hospital mortality was defined as death due to any cause during hospitalization.
A total of 129 patients with SSTIs caused by Aeromonas species were enrolled in the study, including 12 patients (9.3%) with underlying malignancy. Clinical manifestations of these 12 cancer patients with Aeromonas SSTIs are summarized in Table 1 . Most of the patients were male (n Z 9, 75%), with two-thirds of them being elderly patients (aged greater than 65 years). A. hydrophila (n Z 6, 50.0%) was the most common pathogen, followed by Aeromonas veronii biovar sobria (n Z 3, 25.0%), Aeromonas caviae (n Z 2, 16.7%), and Aeromonas veronii biovar veronii (n Z 1, 8.3%). Hepatocellular carcinoma was the most common malignancy, followed by cholangiocarcinoma, and gastric cancer. In addition to cancer, diabetes mellitus (n Z 3) and liver cirrhosis (n Z 3) were the most common underlying diseases. Among these patients, 58.3% (n Z 7) had traumarelated wound infections, and only one patient had a history of exposure to aqueous environments prior to infection. Only two patients presented with necrotizing fasciitis. The majority (n Z 10, 83.3%) of patients had polymicrobial SSTIs. The outcome was favorable with an appropriate antibiotic therapy with in vitro activity, with or without surgical intervention, except in one patient with A. caviae infection who had in-hospital mortality.
In the present work, we had two important findings. Firstly, although liver cirrhosis and diabetes mellitus are the most common underlying diseases, which predispose patients to Aeromonas infections, 4 ,5 the present work and Papadakis et al's 1 report show that Aeromonas can cause SSTIs in patients with malignancy, including both solid and hematological cancers. Secondly, consistent with our previous study, 3 most of the cases were caused by polymicrobial infections. Despite these patients being immunocompromised, the outcomes combined with this infection were good in this series.
In conclusion, Aeromonas species should be considered as an etiology of SSTIs among cancer patients. 
